Pimecrolimus + Vehicle

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Keratoconjunctivitis Sicca

Conditions

Keratoconjunctivitis Sicca

Trial Timeline

Sep 1, 2004 → Dec 1, 2006

NCT ID

NCT00128245

About Pimecrolimus + Vehicle

Pimecrolimus + Vehicle is a phase 2 stage product being developed by Novartis for Keratoconjunctivitis Sicca. The current trial status is completed. This product is registered under clinical trial identifier NCT00128245. Target conditions include Keratoconjunctivitis Sicca.

What happened to similar drugs?

1 of 9 similar drugs in Keratoconjunctivitis Sicca were approved

Approved (1) Terminated (0) Active (8)

✅Cyclosporine A + DexamethasoneNovartisApproved

🔄FK506Astellas PharmaPhase 3

🔄FK506 + placeboAstellas PharmaPhase 3

🔄OTX-101 0.09%Sun PharmaceuticalPhase 3

🔄cyclosporine + vehicle of OTX-101Sun PharmaceuticalPhase 3

🔄INS365 Ophthalmic SolutionMerckPhase 3

🔄RebamipideNovartisPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00128245	Phase 2	Completed	Sep 1, 2004	Dec 1, 2006	Keratoconjunctivitis Sicca

Competing Products

15 competing products in Keratoconjunctivitis Sicca

See all competitors

Product	Company	Stage	Hype Score
FK506	Astellas Pharma	Phase 3	40
FK506 + placebo	Astellas Pharma	Phase 3	40
OTX-101 0.09%	Sun Pharmaceutical	Phase 3	40
OTX-101 0.05% + OTX-101 0.09% + Vehicle	Sun Pharmaceutical	Phase 2/3	38
cyclosporine + vehicle of OTX-101	Sun Pharmaceutical	Phase 3	40
INS365 Ophthalmic Solution	Merck	Phase 3	40
Cyclosporine A + Dexamethasone	Novartis	Approved	43
Rebamipide	Novartis	Phase 3	40
Rebamipide	Novartis	Phase 3	40
Tasocitinib + Tasocitinib + vehicle for Tasocitinib	Pfizer	Phase 2	27
Dupilumab	Regeneron Pharmaceuticals	Phase 2	31
R348 Ophthalmic Solution, 0.2% + R348 Ophthalmic Solution, 0.5% + R348 Ophthalmic Solution, 1.0% + Placebo	Rigel Pharmaceuticals	Phase 1	23
R348 Ophthalmic Solution, 0.2% + R348 Ophthalmic Solution, 0.5% + Placebo	Rigel Pharmaceuticals	Phase 2	29
CF101	Can Fite Biopharma	Phase 3	30
CF101 + Placebo	Can Fite Biopharma	Phase 2	25